We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Commonwealth Biotechnologies, Inc. Completes Acquisition of Mimotopes Pty Ltd,
News

Commonwealth Biotechnologies, Inc. Completes Acquisition of Mimotopes Pty Ltd,

Commonwealth Biotechnologies, Inc. Completes Acquisition of Mimotopes Pty Ltd,
News

Commonwealth Biotechnologies, Inc. Completes Acquisition of Mimotopes Pty Ltd,

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Commonwealth Biotechnologies, Inc. Completes Acquisition of Mimotopes Pty Ltd,"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Commonwealth Biotechnologies, Inc. (CBI) has announced that it has acquired all of the outstanding capital stock of Mimotopes Pty Ltd (Mimotopes), a global leader in high quality research-grade peptide products and applications for the drug discovery industry.

Upon completion of the transaction, Mimotopes’ Executive Director Dr. Paul D’Sylva, was appointed to the Board of Directors of CBTE and installed as Chief Executive Officer of the combined entity.

Dr. D’Sylva brings to the company a strong commercial focus and a wealth of experience in capital raising, financial management, and business development.

According to Dr. D’Sylva, “CBI’s expertise in proteomics, immunology and genomics coupled with Mimotopes’ expertise and proprietary technologies in peptide and synthetic chemistry provides a solid foundation upon which to grow an integrated research services company targeting the $5 billion and growing market for drug discovery outsourcing.

The business model for CBI will be to maintain a disciplined approach to providing dedicated research services to the drug discovery industry on a fee-for-service basis in order to maximize revenue and profit growth.”

The transaction positions CBI for sustained growth through the:
• Realization of cost synergies and revenue synergies that will accelerate cash flow growth;
• Provision of a trained and experienced sales and marketing force with offices located across the United States, the United Kingdom and Australia; and
• Alignment of business product and service capabilities with industry growth.

Dr. Richard Freer, Chairman and COO of CBI, said that “We at CBI are very excited about the potential this new combined entity has to grow its top line revenue and bottom line result. The synergies between the companies, the addition of new management skills, partnerships with major life science companies, and a global sales presence, are all reasons to be optimistic for the future.”

Advertisement